Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.50 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.50 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.50 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.50 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.50 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.50 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.50 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.31 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.31 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.31 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.31 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.31 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.31 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.31 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.31 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.31 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.31 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13162564 | 0.98 | GABRA1 (0.52) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| Hydrochloric Acid SCHEMBL440466 | 0.85 | TSHR (0.45) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL408176 | 0.82 | TSHR (0.46) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL2051129 | 0.79 | — | — | |
| SCHEMBL29061152 | 0.77 | LMNA (0.46) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL5247560 | 0.77 | LMNA (0.42) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL20137931 | 0.76 | LMNA (0.45) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| Hydrochloric Acid SCHEMBL336468 | 0.75 | GABRA1 (0.54) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| Hydrochloric Acid SCHEMBL21640729 | 0.75 | APLNR (0.32) | APLNR | |
| SCHEMBL14836687 | 0.74 | GABRA1 (0.48) | GABRA1TSHRGABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344338-A | Substituted 4-aminoisoindoline-1, 3-dione compounds and their use for the treatment of lymphomas | 细胞基因公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240217955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2024-07-04 | — | — | US | disclosed |
| CN-111989322-B | Substituted 4-aminoisoindoline-1, 3-dione compounds and their use for the treatment of lymphomas | 细胞基因公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-113214220-B | Substituted 4-aminoisoindoline-1, 3-dione compounds and their use for the treatment of lymphomas | 细胞基因公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11945804-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2024-04-02 | — | — | US | disclosed |
| EP-4272737-A2 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND THEIR USE FOR TREATING LYMPHOMA | Celgene Corporation (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3784663-B1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND THEIR USE FOR TREATING LYMPHOMA | CELGENE CORP (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20220306611-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2022-09-29 | — | — | US | disclosed |
| US-11358952-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2022-06-14 | — | — | US | disclosed |
| CN-113214220-A | Substituted 4-aminoisoindoline-1, 3-dione compounds and their use for treating lymphomas | 细胞基因公司 | 2021-08-06 | — | — | CN | disclosed |
| EP-3784663-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND THEIR USE FOR TREATING LYMPHOMA | Celgene Corporation (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-111989322-A | Substituted 4-aminoisoindoline-1, 3-dione compounds and their use for treating lymphomas | 细胞基因公司 | 2020-11-24 | — | — | CN | disclosed |
| US-20190322647-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2019-10-24 | — | — | US | disclosed |
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945804-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith | AANAT, HTR2C, AADAT | GABRA1 1179/4885GABRG2 2356/4885GABRB3 609/4885 |
| US-20240217955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AANAT, HTR2C, AADAT | GABRA1 1179/4885GABRG2 2356/4885GABRB3 609/4885 |
| US-20190322647-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AANAT, HTR2C, AADAT | GABRA1 1179/4885GABRG2 2356/4885GABRB3 609/4885 |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | GABRA1 657/4885GABRG2 1184/4885GABRB3 679/4885 |
| US-11358952-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith | AANAT, HTR2C, AADAT | GABRA1 1179/4885GABRG2 2356/4885GABRB3 609/4885 |
| US-20220306611-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AANAT, HTR2C, AADAT | GABRA1 1179/4885GABRG2 2356/4885GABRB3 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.